Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
330
datasets available to search
ShareScore release 0.9.0
Dataset results
330 results for “anticancer”
Green Synthesis of Zinc Oxide (ZnO) Nanoparticles Using Aqueous Extract of Shilajit: Their Characterization and Anticancer Activity
<p>UV analysis of aqueous extract of shilajit and zinc oxide nanoparticles (ZnO NPs) of shilajit extract showed the absorbance peaks at 422.40 nm and 357.90 nm. The abosrbance peaks confirms the presence of ZnO NPs in the reaction mixture.</p> <p>The FTIR spectrum of shilajit extract and ZnO NPs of shilajith extract showed the strong broad absorbance at 3428 cm−1 are due to the stretching vibration of hydroxyl (OH) functional groups. The absorption band at 1633 cm-1 corresponded the stretching vibration of N-H groups. The peak at 1414 cm<sup>-1</sup> observed in the spectrum indicate the presence of mono-substituted alkynes. The peak at 1163 cm<sup>-1</sup> showed the presence of C-O bonds.</p> <p>The XRD pattern of ZnO NPs of shilajith extract, characterized by their high intensity, were observed at specific 2θ peak values, namely 31.69°, 34.33°, 36.17°, 47.45°, 56.52°, 62.77°, 67.87° and 68.99°, and can be attributed to the lattice planes (100), (002), (101), (102), (110), (103), (112), and (201), respectively.</p> <p>The particle size of ZnO NPs of shilajit extract was measured to be 348 nm and the polydispersity index was found to be 0.322.</p>
RV001V, a RhoC Anticancer Vaccine, Against Metastasis From Solid Tumours
ClinicalTrials.gov study NCT03199872. IPD Sharing: NO. Countries: 1. Publications: 1.
Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies
ClinicalTrials.gov study NCT03353753. IPD Sharing: NO. Countries: 13. Publications: 3.
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
ClinicalTrials.gov study NCT03755791. IPD Sharing: NO. Countries: 34. Publications: 3.
Efficacy of a Systematic Referral to Palliative Care of Patients Who Need for Palliative Care During an Unscheduled Visit in Comprehensive Anticancer Centers
ClinicalTrials.gov study NCT06150027. IPD Sharing: NO. Countries: 1. Publications: 1.
Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines
ClinicalTrials.gov study NCT04535401. IPD Sharing: YES. Countries: 1. Publications: 1.
Data from: Intrinsic growth heterogeneity of mouse leukemia cells underlies differential susceptibility to a growth-inhibiting anticancer drug
Open the record for dataset details and reuse information.
Cystargolide-based amide and ester Pz analogs as proteasome inhibitors and anticancer agents
Open the record for dataset details and reuse information.
Synergistic anticancer activity of resveratrol-loaded polymeric nanoparticles and sunitinib in colorectal cancer treatment
Open the record for dataset details and reuse information.
Dataset for Utilizing Pathway Dependency and Network Representation of Anticancer Drug Sensitivity for Drug Synergy Prediction
Open the record for dataset details and reuse information.
Anticancer bioactive peptide combined with oxaliplatin against gastric cancer by regulation of PI3K/AKT signaling via inhibition of TPX2
Open the record for dataset details and reuse information.
Long-term memory T cells as preventive anticancer immunity elicited by TuA-derived heteroclitic peptides
<p>The host’s immune system may be primed against antigens during the lifetime (e.g. microorganisms antigens—MoAs), and swiftly<br> recalled upon growth of a tumor expressing antigens similar in sequence and structure. C57BL/6 mice were immunized in a preventive<br> setting with tumor antigens (TuAs) or corresponding heteroclitic peptides specific for TC-1 and B16 cell lines. AQ1 Immediately or 2-<br> months after the end of the vaccination protocol, animals were implanted with cell lines. The specific anti-vaccine immune response as<br> well as tumor growth were regularly evaluated for 2 months post-implantation. The preventive vaccination with TuA or their<br> heteroclitic peptides (hPep) was able to delay (B16) or completely suppress (TC-1) tumor growth when cancer cells were implanted<br> immediately after the end of the vaccination. More importantly, TC-1 tumor growth was significantly delayed, and suppressed in 6/8<br> animals, also when cells were implanted 2-months after the end of the vaccination. The vaccine-specific T cell response provided a<br> strong immune correlate to the pattern of tumor growth. A preventive immunization with heteroclitic peptides resembling a TuA is able<br> to strongly delay or even suppress tumor growth in a mouse model. More importantly, the same effect is observed also when tumor<br> cells are implanted 2 months after the end of vaccination, which corresponds to 8 – 10 years in human life. The observed potent tumor<br> control indicates that a memory T cell immunity elicited during the lifetime by a antigens similar to a TuA, i.e. viral antigens, may<br> ultimately represent a great advantage for cancer patients and may lead to a novel preventive anti-cancer vaccine strategy.</p>
Screening Process and Eligibility Decision for SR Anticancer Effects Curcumin, Shogaols, and Gingerols
<p>A dataset consisting of list of studies together with their inclusion/exclusion decision for</p> <p>a. Sheet 1: Excluded studies with reason(s) from electronic database search</p> <p>b. Sheet 2: Included studies from electronic database search</p> <p>c. Sheet 3: Decision on full-text screening</p> <p>d. Sheet 4: Decision on studies retrieved from other sources</p>
Knowledge-driven design and optimization of potent symmetric anticancer molecules: A case study on PKM2 activators
<p>All the raw data files including 3D structures of all the 200 virtually designed palindromic and non-palindromic activators, 3D structures of top 5 palindromic and non-palindromic activators in complex with PKM2 protein, starting and ending conformations of MD simulation structures with the .tpr files for all six simulations for PDA116 and NPDA4 are available in this dataset.</p>
Fig. 7 in Exploration of anticancer potential of Lantadenes from weed Lantana camara: Synthesis, in silico, in vitro and in vivo studies
Fig. 7. Effect of 3β-(4-Methoxybenzoyloxy)-22β-senecioyloxy-olean-12-en-28-oic acid (10) on: (A) DMBA/TPA induced skin tumorigenesis, (B) growth of lesions.
Fig. 4 in Exploration of anticancer potential of Lantadenes from weed Lantana camara: Synthesis, in silico, in vitro and in vivo studies
Fig. 4. (a). 1Le9 receptor; 4(b). 3QA8 receptor: Indicating new cartoon and stick model along with binding cavity in yellow colour. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Fig. 5. 3D in Exploration of anticancer potential of Lantadenes from weed Lantana camara: Synthesis, in silico, in vitro and in vivo studies
Fig. 5. 3D ribbon representation and zoom view: (A) Doxorubicin in the binding pocket of NF-κB (1Le9), (B) compound 10 in the binding pocket of NF-κB (1Le9), (C) Doxorubicin in the binding pocket of IKK-β (3QA8), (D) Compound 10 in the binding pocket of IKK-β (3QA8).
Fig. 3 in Exploration of anticancer potential of Lantadenes from weed Lantana camara: Synthesis, in silico, in vitro and in vivo studies
Fig. 3. Cell viability of Lantadenes (1–2), reduced Lantadenes (3–4) and Lantadene ester derivatives (5–10) against: (A) A375 cell line, (B) A431 cancer cell line using SRB assay. Each point represents a mean value and SEM of 3 independent experiments. ANOVA was applied followed by Tukey's test.
Fig. 10 in Kiiacylphnols A H, eight undescribed polycyclic polyprenylated acylphloroglucinols with anticancer activities from Hypericum przewalskii Maxim
Fig. 10. Effects of compounds 1 and 10 to cancer cell lines. HL60 and SU-DHL-4 cells were exposed to vehicle control (DMSO, <0.1%), compounds 1 or 10 for 48 h, respectively. (A) Dose-dependent viability curves for two cancer cell lines after treatment with 1 and 10 (mean ± SD for three independent experiments). (B) The IC50 of 1 and 10 were calculated using the SPSS software. (C–D) Cells were harvested after 1 or 10 treatment and apoptosis was determined by Annexin V-FITC and PI staining using flow cytometry analysis. Data are expressed as the mean SD of three independent experiments. #p <0.05, **p <0.01, ****p <0.001, unpaired two± tailed Student's t-test.
Fig. 6 in Genomic data mining approaches for the discovery of anticancer peptides from Ganoderma sinense
Fig. 6. Three-dimensional structures of P14 and P15, shown in cartoon representation; red represents α-helix, yellow represents β-sheet, and blue represents turn structure. Structures were extracted from the trajectory of molecular dynamic simulation from 20 ns to 100 ns. The lowest energy conformation is presented. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.